ArticleScientific reports2026
Identification of epithelial, mesenchymal, and platelet-associated circulating tumour cells with translational implications in oral squamous cell carcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Metastatic dissemination is driven by rare Circulating Tumour Cells (CTCs) that exhibit pronounced phenotypic plasticity and dynamic interactions with different components in the bloodstream. In Oral Squamous Cell Carcinoma (OSCC), limited resolution of epithelial, mesenchymal, and platelet-associated CTC-states has constrained biological understanding of early tumour spread and hindered translational interpretation. In this study, we identify, count and characterize distinct epithelial, mesenchymal, and platelet-associated CTC-states in a cohort of 33 patients using a strategic workflow involving hematopoietic cell depletion with multiparametric flow-cytometric analysis. The FACS (Fluorescence-assisted cell sorting)-strategy incorporated epithelial tumour-associated markers (EpCAM, EGFR, and Cytokeratin), mesenchymal markers (VIM and N-Cadherin), and platelet/leukocyte markers (CD41 and CD45) to resolve biologically distinct CTC-subpopulations. Analytical robustness was established through spike-in experiments using OSCC cell line i.e., Cal27, demonstrating linear detection across clinically relevant ranges(1-100cells/mL of blood, Spearman's r = 0.8738, p < 0.0001) and sensitive recovery of rare tumour cells with a Limit of Detection of 1 cell/mL, Limit of Quantification of 10 cells/mL, and Limit of Blank of 1.779 cells/mL. Molecular validation of sorted populations using whole transcriptome amplification-quantitative PCR confirmed tumour-associated marker expression and absence of hematopoietic contamination. Application of this approach in OSCC patients revealed detectable CTCs in 70% of the cases (ranging from 14.20 to 340.5 CTCs-related events/mL). Importantly, CTCs were identified across discrete phenotypic states, including platelet-associated CTC-clusters that were not captured by epithelial marker-restricted strategies. Quantitative comparison of CTC subtype proportions revealed majority (nearly 83%) of CTCs present as platelet clusters, followed by Epithelial-Single CTCs (21.21%). In comparison, CTCs with only mesenchymal phenotype constitute only 3.22% of the total CTC-population. Receiver operating characteristic analysis supported the discriminatory capacity of CTC enumeration and enabled the definition of a biologically relevant threshold of > 19.40 events mL for CTC positivity. Taken together, our findings outline a practical workflow for identifying and quantifying different CTC-states in OSCC, with platelet-associated CTCs emerging as the predominant population detected. These findings support the importance of incorporating phenotypic heterogeneity and platelet-associated tumour cell interactions into future liquid biopsy-based translational pathology research and clinical biomarker development in OSCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.